UNIVERSITY OF LEICESTER, LOUGHBOROUGH UNIVERSITY
&
UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST

JOINT RESEARCH SUPPORT OFFICE

STANDARD OPERATING PROCEDURES

UHL Research Support Office
SOP S-1031 UHL v5 October 2018

Standard Operating Procedure for Data Management Process for Research sponsored by University Hospitals of Leicester NHS Trust (UHL)

PGC Reference No: C39/2014

OFFICE BASE

Research & Innovation
Leicester General Hospital
Gwendolen Road
Leicester
LE5 4PW
1. Introduction

The purpose of this Standard Operating Procedure (SOP) is to provide guidance for managing data and ensuring all data are collected, verified and analysed in the appropriate manner for all research studies sponsored by the University Hospitals of Leicester NHS Trust (UHL).

Data management processes are required to ensure that the data included in the clinical trial report or publication of the trial results are accurate and were captured in accordance with the approved clinical trial protocol.

2. Scope

This SOP applies to all research studies sponsored by the UHL.

3. Definition

The data management process covers the design and production of the data capture tool (see UHL SOP S-1035, Case Report Form (CRF) production), the design and construction of the database, the processing of data (entry, uploading, cleaning and query management) and production of the final dataset(s) ready for analysis. Quality control must be applied at each stage of data handling to ensure that all data are reliable and have been processed correctly.

4. Delegation

In accordance with Good Clinical Practice (GCP), data handling must be conducted by appropriately qualified and trained individuals. As Sponsor, UHL delegates the responsibility for data management to the Chief Investigator (CI) for each individual study. Where this is further delegated to another member of the research team it must be clearly documented on the Delegation of Authority and Signature Log (Appendix 1 SOP S-1005 UHL). When delegated to an external organisation, the roles and responsibilities will be clearly detailed in an appropriate agreement.

5. Computer System Validation

There are three key features of computer system validation which must be complied with and for which there must be documentary evidence. These are:

- Appropriate controls of the system are in place throughout the system's lifetime
- Documentation is available to support the application of the controls
- The system is fit for purpose and performs reliably and consistently as intended

The database system is then used to create a trial-specific database and data entry system. This must also be validated to confirm that the database system is fit for purpose specifically for the trial.

There must be a mechanism in place for version control of the system and a formal process to manage any changes to this to ensure the validated state is maintained.
5.1 Choice of Data Management Database

UHL conducts a wide range of research studies ranging from simple qualitative studies to complex highly regulated Clinical Trials of Investigational Medicinal Products (CTIMPs). The type of database used needs to be proportionate to the risk associated with the study and this will be determined during the Sponsor Risk Assessment process. Where possible the services of a Clinical Trial Unit (CTU) should be used.

Whilst the type of database used will be proportionate with the associated risk, the underlying principles remain the same in that the Sponsor must ensure that adherence to the principles of GCP which include "All clinical trial information should be recorded, handled and stored in a way that allows its accurate reporting, interpretation and verification" are followed.

For small simple trials where the results are not going to be used in a marketing authorisation application MS Excel may be considered appropriate to be used for the data management and analysis rather than a formal clinical trial database. Whatever system is chosen, appropriate validation must be conducted and all transactions must have a clear and complete audit trail. For some software, e.g. MS Excel, this may necessitate the printing of data and the certification and dating of the data as an accurate record.

5.2 Electronic Trial Data Handling Systems

When using electronic trial data handling or remote electronic trial data systems the following Sponsor requirements must be complied with:

a) The system must be validated and there must be documentary evidence of the validation
b) SOPs must be in place for use of the system
c) The system must be designed in such a way that there is no deletion of entered data (i.e. an audit trail is maintained)
d) A security system must be in place which prevents unauthorised access to the data
e) A list must be maintained of the individuals authorised to make data changes
f) The data must be adequately backed up
g) The blinding (if applicable) must be maintained during data entry and processing
h) If data are transformed during processing it should always be possible to compare the original data and observations with the processed data
i) An unambiguous subject identification code should be used which allows identification of all the data reported for each subject.

6. Data Entry/Capture

The investigator must ensure the accuracy, completeness, legibility and timeliness of the data reported in the case report forms (CRFs). Prior to data entry when using a paper CRF, the form must be reviewed for any missing data, incomplete fields or data outside normal ranges. If discrepancies are picked up at this stage they must be clarified with the Chief Investigator (CI) or delegated individual and any changes recorded, initialed and dated. The original data entry must not be obscured. In addition, any CRF data derived from source documents must be consistent with the source documents or the discrepancy explained. On completion of the above process, the data must be entered into the database by a delegated member of the research team. The data entry process must be defined for each specific study.
7. Data Validation
The aim of data validation is to generate a database/dataset that is of appropriate quality as decided as part of the risk assessment and defined in written procedures, data management plan and/or protocol. It is the process of checking the data for such elements as logical consistency, protocol deviations and missing/incorrect/implausible data. To achieve this formalised validation or edit, checks must be put in place. These can be manual, electronic or a mixture of both. These processes identify data issues that can then be resolved by clarification with the Investigator and/or vendors/holders of related databases (for example laboratory analysis vendors). When all data cleaning and data validation has been completed, the data must be formally declared ‘clean’ and the database locked for analysis.

8. Database/Dataset Lock
The aim of the data management process is to provide a high quality and appropriately clean final database/dataset suitable for statistical analysis. There must be a process for controlling this and it must be clear when the database/dataset is declared as final, what has been checked in order to make the decision, how the final database is made available, where the final database is stored and how it is accessed and protected.

A checklist to confirm what activities have been completed is recommended. Examples of activities that may be included on the list are:

- All the data queries have been closed
- Pharmacovigilance reconciliation has been completed
- All electronic data have been received, uploaded and validated
- The statistical analysis plan has been approved.

For a more simple situation, for example involving use of a spreadsheet, a file note signed by the person responsible, together with the properties of the MS Excel file (for example, date/time stamped, file location), would be sufficient to confirm that the data are final.

When a clean dataset is required at time points other than the end of the trial, for example, at the time of an interim analysis or for data monitoring committee meetings, the same principles apply as to the final database. However, it might also be appropriate, dependent on the purpose of the analysis, to provide ‘un-cleaned’ databases/datasets in certain circumstances.

How the database is “physically” locked will depend very much on the individual trial but the outcome is that the data are protected from editing or deleting. Whatever the situation, the lock procedure must be appropriately robust to protect the final data and there must be documentation and an ability to demonstrate how and when the physical lock was done.

9. Unlocking the final Database/Dataset
Occasionally it may be necessary to correct previously missed data errors or inconsistencies after the data have been released for analysis. There must therefore be a process in place to resolve this by unlocking the database, correcting the data and providing new extracted datasets after the query has been resolved. However, unlocking a final locked database or dataset must be limited to important corrections (that is if the data to be changed will have a significant impact on the reliability of the results) and the final trial report must include details of all changes made to the database while it was unlocked.
10. Data Back Up and Disaster Recovery

It is essential that research data is backed up in accordance with UHL IT policies. Further information and help can be found through UHL IM&T.

11. Responsibilities

<table>
<thead>
<tr>
<th>Responsibility</th>
<th>Undertaken by</th>
<th>Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Sponsor &amp; CI</td>
<td>Head of Research Operations &amp; CI</td>
<td>Determine type of database required at Sponscr Risk Assessment &amp; Sponsor review</td>
</tr>
<tr>
<td>2 CI</td>
<td>CI or delegate</td>
<td>Ensure the accuracy, completeness, legibility and timeliness of data reported in the CRFs.</td>
</tr>
<tr>
<td>3 CI, Research Team Data Management Responsible, Clinical Trial Monitor</td>
<td>CI, Research Team Data Management Responsible, Clinical Trial Monitor</td>
<td>QC throughout the data management process</td>
</tr>
<tr>
<td>4 Sponsor &amp; CI</td>
<td>Head of Research Operations or Delegate &amp; CI</td>
<td>Ensure that any external providers have been identified as part of the Sponsor Risk Assessment Process and appropriate agreements in place before data capture begins.</td>
</tr>
</tbody>
</table>
This table is used to track the development and approval of the document and any changes made on revised/reviewed versions.

**DEVELOPMENT AND APPROVAL RECORD FOR THIS DOCUMENT**

<table>
<thead>
<tr>
<th>Author / Lead Officer:</th>
<th>Joanne Thompson / Carolyn Maloney</th>
<th>Job Title: Medical Writer, Clear Clinical Research Ltd / Head of Research Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reviewed by:</td>
<td>UHL R&amp;I Management Meeting.</td>
<td></td>
</tr>
<tr>
<td>Approved by:</td>
<td>Professor Nigel Brunskill</td>
<td>Date Approved: 18/2/19</td>
</tr>
</tbody>
</table>

**REVIEW RECORD**

<table>
<thead>
<tr>
<th>Date</th>
<th>Issue No.</th>
<th>Reviewed By</th>
<th>Description Of Changes (If Any)</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 2015</td>
<td>2</td>
<td>Carolyn Maloney</td>
<td>Changes to Logo and corporate identity</td>
</tr>
<tr>
<td>August 2016</td>
<td>3</td>
<td>CM, LW, JJ</td>
<td>Consistency checks</td>
</tr>
<tr>
<td>February 2017</td>
<td>4</td>
<td>Carolyn Maloney</td>
<td>Update to logo.</td>
</tr>
<tr>
<td>October 2018</td>
<td>5</td>
<td>VW, CCL, JJ, SM</td>
<td>Consistency checks.</td>
</tr>
</tbody>
</table>

**DISTRIBUTION RECORD:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Name</th>
<th>Dept</th>
<th>Received</th>
</tr>
</thead>
</table>